Last reviewed · How we verify
Injectable clostridial collagenase
Injectable clostridial collagenase breaks down collagen in fibrotic tissue, allowing mechanical disruption of contractures and scar tissue.
Injectable clostridial collagenase breaks down collagen in fibrotic tissue, allowing mechanical disruption of contractures and scar tissue. Used for Dupuytren's contracture, Peyronie's disease.
At a glance
| Generic name | Injectable clostridial collagenase |
|---|---|
| Also known as | Xiaflex |
| Sponsor | Indiana Hand to Shoulder Center |
| Drug class | Collagenase enzyme |
| Target | Collagen (types I and III) |
| Modality | Biologic |
| Therapeutic area | Orthopedics / Hand Surgery |
| Phase | FDA-approved |
Mechanism of action
Clostridial collagenase is a protease enzyme derived from Clostridium histolyticum that specifically degrades collagen types I and III, the primary structural components of fibrotic tissue. When injected directly into pathological collagen deposits, it enzymatically cleaves the collagen matrix, weakening the tissue architecture and enabling manual manipulation or passive stretching to restore mobility and function.
Approved indications
- Dupuytren's contracture
- Peyronie's disease
Common side effects
- Injection site pain or swelling
- Bruising or hematoma
- Allergic reaction
- Tendon rupture (rare)
Key clinical trials
- Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease (PHASE4)
- Concurrent Low Intensity Shockwave Therapy on Collagenase Clostridium Histolyticum for Peyronie's Disease (NA)
- A Study to Assess Collagenase Clostridium Histolyticum (CCH) in the Treatment of Plantar Fasciitis (PFA) (PHASE2)
- Fasciectomy vs Collagenase Injection in Recurrent Dupuytren Disease (PHASE4)
- Trial Comparing Treatment Strategies in Dupuytren's Contracture (PHASE4)
- Study of Different Interventions to Reduce Bruising Following CCH-Aaes Treatment for Cellulite of the Buttocks (PHASE2)
- Effectiveness of Splinting After Collagenase Injection (PHASE3)
- Delayed Dose Collagenase Clostridium Histolyticum (CCH) Protocol for Men With Peyronie's Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: